Back to top
more

Thermo Fisher Scientific (TMO)

(Delayed Data from NYSE)

$624.21 USD

624.21
1,302,890

+3.79 (0.61%)

Updated Sep 10, 2024 04:00 PM ET

After-Market: $623.39 -0.82 (-0.13%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (67 out of 250)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Thermo Fisher Scientific is a scientific instrument maker and a world leader in serving science. In Nov 2006, Thermo Fisher Scientific, Inc. was formed through the merger of Thermo Electron Corporation with Fisher Scientific International Inc. On Feb 3, 2014, Thermo Fisher acquired Life Technologies Corporation. Following the acquisition, the new reporting segments are: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Quest Diagnostics (DGX) Beats Earnings in Q3, Updates View

by Zacks Equity Research

Despite hurricanes related financial impact, Quest Diagnostics (DGX) posted year-over-year growth in Q3 on recent acquisitions, tie-ups and strength in several advanced diagnostic offerings.

    Varian Medical (VAR) Initiates Halcyon Treatment in Europe

    by Zacks Equity Research

    Varian (VAR) has been taking initiatives to gain customers for its broad spectrum of products, especially targeting emerging markets.

      Abbott (ABT) Exceeds Q3 Earnings, '17 Guidance Narrowed

      by Zacks Equity Research

      Abbott (ABT) posted promising Q3 results primarily on the back of strong EPD sales and emerging market expansion.

        Will Recall Issue Hurt Boston Scientific (BSX) Q3 Earnings?

        by Zacks Equity Research

        Although Boston Scientific's (BSX) recent $435-million acquisition of Symetis SA might drive its IC business, the company's full recovery post a primary product recall may however, take time.

          What to Expect From Thermo Fisher (TMO) in Q3 Earnings

          by Zacks Equity Research

          Thermo Fisher (TMO) gears up for another quarter of strong analytical instruments segmental growth. Improvement is likely to be seen in applied markets too.

            Phibro Animal Banks on Diverse Portfolio, Competition Rife

            by Zacks Equity Research

            Phibro Animal (PAHC) is consistently trying to expand its product portfolio to counter the tough competition in the animal health space.

              Henry Schein (HSIC) Inks Distribution Agreement with Terason

              by Zacks Equity Research

              Henry Schein's (HSIC) distribution agreement with Terason to distribute the latter's uSmart 3200T NexGen is likely to boost its global Medical segment business.

                Here's Why You Should Buy Thermo Fisher Scientific (TMO) Now

                by Zacks Equity Research

                Based on a wide range of fundamental factors, Thermo Fisher (TMO) is a great pick for now.

                  Here's Why Investors Should Buy Integra LifeSciences Now

                  by Zacks Equity Research

                  The market is upbeat about Integra LifeSciences' (IART) latest developments that include product launches and strategic buyouts.

                    TransEnterix Senhance Surgical Robotic System Wins FDA Nod

                    by Zacks Equity Research

                    TransEnterix (TRXC) works on expanding in robotic surgery consistently.

                      Henry Schein Gains on Strategic Buyouts, Cost Concern a Woe

                      by Zacks Equity Research

                      Henry Schein (HSIC) continues to grow on dental and animal health business, thanks to merger and acquisition activity. However, rising costs continue to be a burden on the company's bottom line.

                        NuVasive's (NUVA) PRECICE System Gets Expanded FDA Approval

                        by Zacks Equity Research

                        NuVasive's (NUVA) latest receipt of expanded FDA 510(k) approval for PRECICE is likely to fortify its hold in the limb reconstruction and trauma market.

                          Abbott Banks on FDA Approvals and Buyouts, Competition Rife

                          by Zacks Equity Research

                          The market is upbeat about Abbott's (ABT) latest initiatives.

                            Bruker (BRKR) at a 52-Week High: What's Driving the Stock?

                            by Zacks Equity Research

                            The new 52-week high of Bruker (BRKR) came on the back of several new initiatives, the most recent one being the introduction of the new CE-IVD marked Fungiplex Candida fast diagnostic assay.

                              MedTech Players Eyeing Emerging Market Growth Opportunities

                              by Zacks Equity Research

                              The gloomy eco-political scenario in the United States and Europe points toward the fact that emerging geographies are playing a crucial role in the growth of the MedTech space globally.

                                LabCorp (LH) Strong on Strategic Planning, Competition Rife

                                by Zacks Equity Research

                                LabCorp (LH) grows on strong diagnostics business amid softness in the Covance drug development business.

                                  DENTSPLY SIRONA Strong on Deal Renewals, Forex Woes Stay

                                  by Zacks Equity Research

                                  DENTSPLY SIRONA's (XRAY) renewed distribution deal will aid the company to gain market traction. However, forex woes remain a concern.

                                    Henry Schein Closes Merritt Buyout, Expands in Animal Health

                                    by Zacks Equity Research

                                    Henry Schein (HSIC) is consistently trying to expand its Animal Health business.

                                      CryoLife to Buy JOTEC, Preliminary Revenue Result Out for Q3

                                      by Zacks Equity Research

                                      CryoLife (CRY) gained access to the $2-billion global market for stent grafts through JOTEC deal.

                                        Mazor Projects Higher Q3 Revenues, Clinches Mazor X Orders

                                        by Zacks Equity Research

                                        Mazor's (MZOR) strong booking and order backlog from Mazor X system sales is likely to boost fortunes in the global spine surgery space.

                                          QIAGEN Banks on Tie-Ups & Product Launches, Competition Rife

                                          by Zacks Equity Research

                                          The market is upbeat about QIAGEN's (QGEN) partnership and co-marketing agreement with CENTOGENE AG to boost its bioinformatics portfolio.

                                            Express Scripts (ESRX) to Buy eviCore, Fortify PBM Business

                                            by Zacks Equity Research

                                            Express Scripts (ESRX) is consistently trying to expand its core PBM business.

                                              Pacific Biosciences, Bluebee Team Up for De Novo Sequencing

                                              by Zacks Equity Research

                                              With increasing demand for SMRT sequencing in the genomics community, both Pacific Biosciences (PACB) and partner Bluebee expect a huge customer adoption of integrated de novo assembly pipeline.

                                                QIAGEN Partners With CENTOGENE, Boosts Bioinformatics Suite

                                                by Zacks Equity Research

                                                QIAGEN (QGEN) makes another encouraging move to expand its advanced bioinformatics portfolio and add additional capabilities, partners CENTOGENE.

                                                  Illumina (ILMN) Strong on Product Launches, Competition Rife

                                                  by Zacks Equity Research

                                                  Illumina rides high on product launches, including the latest release of VeriSeq NIPT in Europe, and strong uptake of NovaSeq. Weak margins remain a concern.